PEOPLE - Changes at UroGen (US):
This article was originally published in Clinica
US company UroGen has named Dr Robert Sobol president and chief executive officer. Dr Sobol, a founder of IDEC Pharmaceuticals, had previously been executive vice-president and chief operating officer of UroGen. He replaces Paul Quadros who becomes chairman. Dr Sobol also joins the board of directors, together with Victor Schmitt and Dr Wei-Wei Zhang, both from Baxter Healthcare. Following a partnering agreement with Baxter, Urogen has expanded its product line to include diagnostics and treatment for cancer and genetic disorders as well as prostate cancer.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.